NANJING, China, June 24, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that it entered into a share transfer agreement with Zhuhai Rongding Equity Investment Partnership L.P. on June 17, 2013 to sell Simcere's approximately 99.99% equity interest in Jilin Boda pharmaceutical Co., Ltd. ("Boda"), which is currently the manufacturer of Yidasheng, for a cash consideration of RMB400 million.
Simcere holds an approximately 99.99% stake in Boda through acquisitions made since 2007. Upon completion of this transaction, Simcere will no longer hold any equity interest in Boda. Consummation of the transaction is subject to certain closing conditions.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
Investor and Media Contacts:
Jie Liu D'Elia
Simcere Pharmaceutical Group
In the United States:
Brunswick Group LLC
SOURCE Simcere Pharmaceutical Group